A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6137-6147

  Oh, Seunguk ^a   Stish, Brad J ^a   Sachdev, Deepali ^b   Chen, Hua ^a   Dudek, Arkadiusz Z ^b   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC LIGAND DIRECTED TOXIN; EGF4KDEL 7MUT PROTEIN; EPITOPE; GAMMA UROGASTRONE; HYBRID PROTEIN; INTERLEUKIN 4; LUCIFERASE; NEUTRALIZING ANTIBODY; PSEUDOMONAS EXOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; CANCER MODEL; CHRONOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOTOXINS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-4; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349653790     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0696     Document Type: Article

References (30)

1. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-6729 (Pubitemid 46190267)
2. Kioi M, Shimamura T, Nakashima H, et al. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 2009;124: 1440-1448
3. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian and pancreatic cancers. Clin Cancer Res 2007;13:5144-5149 (Pubitemid 47502082)
4. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-8834 (Pubitemid 44893849)
5. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 2008; 105:11311-11316
6. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339:394-397 (Pubitemid 19144230)
7. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58:968-975 (Pubitemid 28182466)
8. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48:899-907.
9. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
10. Obiri NI, Siegel JP, Varricchio F, Puri RK. Expression of high affinity interleukin-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 1994;95:148-155 (Pubitemid 24207118)
11. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005;11:3879-3888 (Pubitemid 40685609)
12. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007;13:3058-3067 (Pubitemid 46849583)
13. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. A bispecific recombinant cytotoxin (DTEGF13) targeting human IL-13 and EGF receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 2007;13:6486-6493 (Pubitemid 350075039)
14. Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33:1233-1242
15. Oh S, Ohlfest JR, Todhunter DA, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol. 2009 June 11 Epub ahead of print.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
17. Vallera DA, Todhunter D, Kuroki DW, et al. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 2005;29:331-341 (Pubitemid 40127061)
18. Young RK, Cailleau RM, Mackay B, Reeves WJ. Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro 1974;9:239-245
19. Morikawa S, Tatsumi E, Baba M, Harada T, Yasuhira K. Two E-rosette-forming lymphoid cell lines. Int J Cancer 1978;21:166-170 (Pubitemid 8271908)
20. Stish BJ, Oh S, Chen H, et al. Design and modification of EGFKDEL 7mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. British J Canc 2009;101:epub ahead of print.
21. Pirker R. Immunotoxins against solid tumors. J Cancer Res Clin Oncol 1988;114:385-393
22. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007;61:1031-1037 (Pubitemid 350306946)
23. Kruisbeek AM. Commonly used mouse strains. Curr Protoc Immunol 2001;Appendix 1: Appendix 1C.
24. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611
25. Kawakami K, Kawakami M, Leland P, Puri RK. Internalization property of interleukin-4 receptor chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells. Clin Cancer Res 2002;8:258-266 (Pubitemid 34101486)
26. Kawakami K, Kawakami M, Husain SR, Puri RK. Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor α chain. Clin Cancer Res 2003;9:1826-1836.
27. Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med 2000;6:165-178
28. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A 1994;91:6889-6893 (Pubitemid 2125970)
29. Vallera DA, Shu Y, Stish BJ, et al. Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL- 13 and EGF receptors in a mouse xenograft model. Gut 2008;57:634-641 (Pubitemid 351579977)
30. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009;2009: 567486. Epub 2009 May 6.